-
Coronavirus: Serum Institute ordered to halt recruitment for vaccine trial
Last updated on Sep 12, 2020, 09:28 am
-
The Drugs Controller General of India (DCGI) has ordered the Serum Institute of India (SII) to pause the recruitment of volunteers for Phase 2 and Phase 3 trials of the coronavirus vaccine, being developed by the University of Oxford and UK-pharma giant AstraZeneca.
This development comes after Pune-based SII paused testing , buoyed by AstraZeneca's decision to suspend trial as a volunteer fell ill.
-
In this articleSII asked to increase monitoring of those who got vaccinated AstraZeneca paused trial after woman fell ill; SII continued process After stern notice, SII also paused trial SII's reply to DCGI led to the latest development Reportedly, phase 3 was set to start soon Shouldn't be discouraged, said WHO on AstraZeneca pause
-
Order
SII asked to increase monitoring of those who got vaccinated
![SII asked to increase monitoring of those who got vaccinated]( "SII asked to increase monitoring of those who got vaccinated")
-
According to PTI, Director Dr. VG Somani also told SII to amp up the safety monitoring of those who got vaccinated. The firm was also directed to submit the report.
Moreover, SII was told it has to get clearance from the Data and Safety Monitoring Board (DSMB), both in UK and in India, before getting a green signal from the regulator for resuming recruitment.
-
Looking back
AstraZeneca paused trial after woman fell ill; SII continued process
-
This week, AstraZeneca informed it was pausing trial globally after a volunteer developed an "adverse reaction" to the vaccine, dubbed as the frontrunner in the global race.
The woman, CEO Pascal Soriot, said had "neurological symptoms consistent with a rare but serious spinal inflammatory disorder." AstraZeneca assured it wouldn't compromise on safety.
Despite a setback around the world, SII went ahead with the process.
-
Series of events
After stern notice, SII also paused trial
-
SII's decision to continue with the trial earned it a notice from DCGI.
In the show-cause notice, the regulator asked the firm why it hadn't informed about AstraZeneca's pause, why it was continuing the trial, and also wondered why the permission shouldn't be revoked.
Hours after the stern communication, SII said it has halted the trial and will resume after AstraZeneca does the same.
-
Reply
SII's reply to DCGI led to the latest development
-
Notably, in its reply, SII noted that India's Data Safety Monitoring Board (DSMB) didn't flag any safety concerns after "the first dose and seven days post-vaccination safety data."
DSMB, however, "recommended pausing further enrollment into the study until ongoing investigations of the issues reported in the UK study is completed," SII added.
This reply formed the basis of DCGI's latest order pertaining to recruitment.
-
Trial
Reportedly, phase 3 was set to start soon
![Reportedly, phase 3 was set to start soon]( "Reportedly, phase 3 was set to start soon")
-
As part of its plan to conduct the trial in India, SII had zeroed in one 17 sites.
Phase 2 of the human trial began in Pune on August 27, but its unclear how many volunteers were administered the vaccine.
The phase 3 trial was supposed to start next week and some 1,600 volunteers were selected, a report in NDTV said.
-
Statement
Shouldn't be discouraged, said WHO on AstraZeneca pause
![Shouldn't be discouraged, said WHO on AstraZeneca pause]( "Shouldn't be discouraged, said WHO on AstraZeneca pause")
-
The AstraZeneca pause, naturally, caused displeasure to a battered globe waiting for a respite from COVID-19.
However, WHO's Chief Scientist Soumya Swaminathan said there's not much to be discouraged about.
"I think this is good... perhaps a wake-up call or lesson for everyone to recognize that there are ups and downs in research, there are ups and downs in clinical development," Swaminathan said.
